NanoViricides, Inc. (NYSE American: NNVC) has submitted an application to the Democratic Republic of Congo’s regulatory agency seeking approval to initiate a Phase II clinical trial of its NV-387 Oral Gummies for the treatment of the current Bundibugyo ebolavirus outbreak. The company announced that it has retained Om Sai Clinical Research Private Limited as the contract research organization for the study, and that drug supplies are already in the DRC.
NV-387 is an orally administered broad-spectrum antiviral designed to target host-side mechanisms that viruses rely on to infect cells. The company believes this approach may reduce the likelihood of viral resistance. The planned study builds on NanoViricides’ ongoing Phase II Mpox trial in the DRC and comes as the company seeks to address an outbreak that, according to the release, has resulted in more than 930 deaths and nearly 2,400 confirmed cases since May.
The company said it believes NV-387’s oral formulation could offer logistical advantages over infusion-based therapies in resource-limited settings. If successful, the treatment could support development of a broad-spectrum therapy for Ebola and other filoviruses.
For more details, the full press release is available at https://ibn.fm/tmrCX.
NanoViricides is a clinical stage company creating special purpose nanomaterials for antiviral therapy. Its lead drug candidate is NV-387, a broad-spectrum antiviral being developed for RSV, COVID, Long COVID, influenza, and other respiratory viral infections, as well as MPOX/smallpox and measles. The company is also developing drugs against HIV, hepatitis B and C, rabies, herpes, influenza, dengue, Ebola, and other viruses. Its platform technology is based on the TheraCour nanomedicine technology, licensed exclusively from TheraCour Pharma, Inc.
As with any drug development, there can be no assurance that NV-387 or other candidates will show sufficient effectiveness and safety for human clinical development. The company notes that the path to typical drug development is extremely lengthy and requires substantial capital.
Latest news and updates relating to NNVC are available in the company’s newsroom at https://ibn.fm/NNVC.
